07 January 2020 | News
CartiLife® is an autologous cartilage-derived chondrocyte cell therapy for the treatment of cartilage defects
Mundipharma has announced that it has sealed an exclusive sales agreement with Bio solution Co., Ltd, a Korea-based leader in cell-based biotechnology, to market and distribute its fourth-generation autologous chondrocyte implantation product, CartiLife.
CartiLife® is an autologous cartilage-derived chondrocyte cell therapy for the treatment of cartilage defects (ICRS grade 3 or 4). Its key benefits include significantly reduced risk of host-immune rejection due to its autologous nature, direct restoration of hyaline cartilage, and a less invasive surgery followed by shorter recovery times compared to the alternative, comparable therapies.
Under the agreement, Mundipharma obtains the rights to market and distribute CartiLife® in South Korea.
"We are delighted to extend our relationship with Bio solution to include CartiLife®, which adds to our portfolio of products for orthopaedic care," said Mundipharma's CEO, Raman Singh. "It is also another example of our support for innovative treatments developed in Asia and our ability to increase their market presence."
This is the second deal between Mundipharma and Biosolution Co., Ltd following the exclusive sales agreement for the allogeneic keratinocyte cell therapy product, KeraHeal-Allo™, which was announced in May 2016.